Cargando…

Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19

Detalles Bibliográficos
Autores principales:	Li, Jing-Xin, Zhu, Feng-Cai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584820/ https://www.ncbi.nlm.nih.gov/pubmed/34774194 http://dx.doi.org/10.1016/S0140-6736(21)02014-6

Ejemplares similares

Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques
por: Yadav, Pragya D., et al.
Publicado: (2021)

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
por: Mohandas, Sreelekshmy, et al.
Publicado: (2021)

Inactivated vaccine Covaxin/BBV152: A systematic review
por: Ahmed, Tousief Irshad, et al.
Publicado: (2022)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
por: Ella, Raches, et al.
Publicado: (2021)

Humoral Immune Response to BBV152 (Covaxin) SARS-CoV-2 Vaccine in Patients on Hemodialysis
por: Vijayaraghavan, Radha, et al.
Publicado: (2023)

Host immune responses in aged rhesus macaques against BBV152, an inactivated SARS-CoV-2 vaccine, and cross-neutralization with beta and delta variants
por: Patil, Dilip R., et al.
Publicado: (2023)

Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study
por: Desai, Devashish, et al.
Publicado: (2022)

Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study
por: Kumar, Nathella Pavan, et al.
Publicado: (2021)

Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine
por: Infimate, DJ L, et al.
Publicado: (2022)

SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India
por: Malhotra, Sumit, et al.
Publicado: (2022)

Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines
por: Choudhary, Hari Ram, et al.
Publicado: (2021)

A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys
por: Singh, Prateek, et al.
Publicado: (2022)

Bbv-152: Subacute thyroiditis: case report
Publicado: (2022)

BBV-152: Myocarditis and myositis: case report
Publicado: (2022)

BBV-152: Herpes zoster: case report
Publicado: (2022)

BBV-152: Reactivation of uveitis : case report
Publicado: (2022)

Managing waning vaccine protection against SARS-CoV-2 variants
por: Leung, Kathy, et al.
Publicado: (2022)

A promising inactivated whole-virion SARS-CoV-2 vaccine
por: Isakova-Sivak, Irina, et al.
Publicado: (2021)

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
por: Ella, Raches, et al.
Publicado: (2021)

Pityriasis Rosea Following Covaxin (BBV152) Vaccination for COVID-19
por: Singh, Bhabani S. T. P., et al.
Publicado: (2022)

Recombinant protein vaccines against SARS-CoV-2
por: Gilbert, Sarah C, et al.
Publicado: (2021)

Dissecting antibody-mediated protection against SARS-CoV-2
por: Zohar, Tomer, et al.
Publicado: (2020)

BBV-152: Cutaneous small vessel vasculitis: case report
Publicado: (2021)

Bbv-152: Cutaneous small-vessel vasculitis: case report
Publicado: (2021)

Factors Associated With the Decay of Anti-SARS-CoV-2 S1 IgG Antibodies Among Recipients of an Adenoviral Vector-Based AZD1222 and a Whole-Virion Inactivated BBV152 Vaccine
por: Selvavinayagam, Sivaprakasam T., et al.
Publicado: (2022)

Single-dose of BBV-152 and AZD1222 increases antibodies against spike glycoprotein among healthcare workers recovered from SARS-CoV-2 infection
por: Parai, Debaprasad, et al.
Publicado: (2021)

A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects
por: Dotiwala, Farokh, et al.
Publicado: (2022)

Neutralizing SARS-CoV-2 Antibody Response and Protective Effect of 2 Doses of ChAdOx1 nCoV-19 and BBV152 Vaccines in Hemodialysis Patients: A Preliminary Report
por: Fernando, Edwin, et al.
Publicado: (2021)

The S-Trimer (SCB-2019) COVID-19 vaccine and reinfection with SARS-CoV-2
por: Li, Jing-Xin, et al.
Publicado: (2022)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

Azd-1222/bbv-152: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
por: Bird, Sarah, et al.
Publicado: (2021)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses
por: Kumar, Nathella Pavan, et al.
Publicado: (2021)

The official French guidelines to protect patients with cancer against SARS-CoV-2 infection
por: You, Benoit, et al.
Publicado: (2020)

Are smokers protected against SARS-CoV-2 infection (COVID-19)? The origins of the myth
por: van Westen-Lagerweij, Naomi A., et al.
Publicado: (2021)

Protecting the vulnerable: SARS-CoV-2 vaccination in immunosuppressed patients with interstitial lung disease
por: Mackintosh, John A, et al.
Publicado: (2021)

Bell's palsy and SARS-CoV-2 vaccines
por: Ozonoff, Al, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in people with HIV
por: Spinelli, Matthew A
Publicado: (2021)

Optimising SARS-CoV-2 vaccination schedules
por: Belda-Iniesta, Cristobal
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_scstiu2sltf8df5557fvt9m8mj